Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

被引：0
|
作者：
Moore, M. [1 ]
Hall, R. [2 ]
Mcloughlin, E. [2 ]
Melson, J. [1 ]
Horton, B. [3 ]
Mills, A. [4 ]
Gentzler, R. [2 ]
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[3] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
[4] Univ Virginia, Pathol, Charlottesville, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
IDO1; NSCLC; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-75
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [21] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Baquerizo, Angeles
    Vavinskaya, Vera
    Rojas, Angela
    Mhoyan, Anna
    Romero-Gomez, Manuel
    Sher, Linda
    Madani, Bahar
    Fisher, Jonathan
    Schaffer, Randolph
    Frenette, Catherine T.
    Marsh, Christopher
    HEPATOLOGY, 2019, 70 : 206A - 206A
  • [22] PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
    Matthew W. Rosenbaum
    Benjamin J. Gigliotti
    Sara I. Pai
    Sareh Parangi
    Heather Wachtel
    Mari Mino-Kenudson
    Viswanath Gunda
    William C. Faquin
    Endocrine Pathology, 2018, 29 : 59 - 67
  • [23] PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
    Rosenbaum, Matthew W.
    Gigliotti, Benjamin J.
    Pai, Sara I.
    Parangi, Sareh
    Wachtel, Heather
    Mino-Kenudson, Mari
    Gunda, Viswanath
    Faquin, William C.
    ENDOCRINE PATHOLOGY, 2018, 29 (01) : 59 - 67
  • [24] PD-L1 and IDO1 expression and clinical outcome in 305 patients with surgically resected esophageal cancer.
    Baba, Yoshifumi
    Ishimoto, Takatsugu
    Hiyoshi, Yukiharu
    Iwatsuki, Masaaki
    Miyamoto, Yuji
    Yoshida, Naoya
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)
    Kim, L.
    Oh, Y.
    Yoon, S. M.
    Park, J. H.
    Chae, Y. K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S152 - S153
  • [26] Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
    Wu, Rui-Yan
    Kong, Peng-Fei
    Xia, Liang-Ping
    Huang, Yun
    Li, Zhi-Ling
    Tang, Yun-Yun
    Chen, Yu-Hong
    Li, Xuan
    Senthilkumar, Ravichandran
    Zhang, Hai-Liang
    Sun, Ting
    Xu, Xue-Lian
    Yu, Yan
    Mai, Jia
    Peng, Xiao-Dan
    Yang, Dong
    Zhou, Li-Huan
    Feng, Gong-Kan
    Deng, Rong
    Zhu, Xiao-Feng
    CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4530 - 4541
  • [27] Joint association of patients' sex and PD-L1 expression with overall survival benefits and tumor-immune microenvironment in immune checkpoint inhibitors for cancers
    Li, Anlin
    Chen, Yongjian
    Zhang, Wenda
    Zhong, Haitao
    Ou, Qiyun
    Gu, Yang
    Xia, Junqing
    Lin, Dagui
    Fu, Tuping
    Liu, Ruixin
    Hu, Hai
    Yu, Yunfang
    Yao, Herui
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (02):
  • [28] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [29] Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
    Horesh, Adi
    Pollack, Rena
    Nechushtan, Hovav
    Dresner-Pollak, Rivka
    Neuman, Tzahi
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [30] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
12345